Acute sunitinib neurotoxicity
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Sunitinib malate is a multitargeted oral tyrosine kinase inhibitor (TKI) which is used in treatment of metastatic renal cell carcinoma with side effects such as diarrhea, mucositis, asthenia and myelosuppression. Serious toxicity associated with sunitinib is a rare situation. However; there are few cases reported in the literature. As a result of the inhibition that is caused by sunitinib malate agent at the receptor level, vascular endothelial growth factor (VEGF) level increases. These increased VEGF levels are considered to having a positive contribution on neurological side effects. Neurotoxicity that is related with the usage of sunitinib malate for two weeks will be presented in this case report. © 2021 The Author(s)
Açıklama
Anahtar Kelimeler
Neurotoxicity, Renal cell cancer, Tyrosine Kinase Inhibitor
Kaynak
Cancer Treatment and Research Communications
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
27
